steroids in palliative care
Last reviewed 01/2018
- patients with advanced malignancy may benefit from corticosteroids for a variety of symptoms
- doses should be tailored to the individual and regularly reviewed, as responses may not be prolonged
- emergency situations, eg spinal cord compression/superior vena cava obstruction - consider IV dexamethasone initially as stat dose, give slowly
- subcutanous route in vomiting (daily bolus)
- dexamethasone is the corticosteroid of choice.
- the bioavailability of dexamethasone is 80%. Generally oral and subcutaneous doses are considered equivalent. Other sources quote dexamethasone to be twice as potent by the subcutaneous route, compared to oral
- where patients have recently discontinued corticosteroids consider additional doses for any circumstances involving physiological stress (pain, infection, trauma)
- prescribe as a single morning dose (or two morning doses if numerous tablets required)
- consider a higher dose of corticosteroids initially to ensure any effect
not missed and review after 3-5 days. Consider the need for higher doses for
patients on phenytoin, carbamazepine, phenobarbitone
- use a 5-7 day corticosteroid 'trial' and unless desired effect achieved,
corticosteroid should be stopped. This can be done abruptly (abrupt withdrawal
of steroids) unless the patient has:
- received less than 3 weeks treatment and
- not received recent repeated courses of corticosteroids
- and
- received doses less than 4-6mg dexamethasone (or equivalent) total daily dose and
- adverse effects are not anticipated by an abrupt withdrawal.
- gradual withdrawal of corticosteroids
- initially reduce rapidly (e.g. halving the dose daily) to physiological doses (dexamethasone 1mg/24h or prednisolone 7.5mg/24h)
- subsequently more gradual reduction is advised (e.g. by 1 - 2mg prednisolone per week)
- patients should be monitored for any deteriorations
- if beneficial, corticosteroids should only be continued at a set dose for a maximum of 2-4 weeks, with planned review date to consider withdrawal
- aim to prescribe the lowest dose that controls the symptoms
- if beneficial, reduce dose by 25% every 3-5 days as symptoms dictate
- watch for symptoms e.g. increased thirst, increased frequency of micturition which might indicate hyperglycaemia
- consider prescribing gastric protectants (e.g. lansoprazole 15- 30mg daily) if at risk (e.g. on a concurrent NSAID, previous history of peptic ulcer disease)
Indications | Treatment and dose range |
Spinal cord compression or cauda equina syndrome Symptoms secondary to cerebral tumour(s). (Headache alone often requires lower dose nerve compression pain |
dexamethasone 16mg per day dexamethasone 16mg per day dexamethasone 8mg per day |
malignant dysphagia intestinal obstruction ureteric obstruction |
dexamethasone 6-16 mg per day |
dyspnoea (pneumonitis after radiotherapy, lymphangitis carcinomatosis, large airways obstruction) | dexamethasone 2-8 mg per day, up to 12mg per day |
pain from hepatic metastases bone pain (occasionally helpful) |
dexamethasone 4-8 mg per day |
antiemetic | dexamethasone 4-8 mg per day |
anorexia* | Dexamethasone 2-4mg / day Prednisolone 15-40mg/day |
rectal discharge | rectal steroid preparations, eg hydrocortisone or prednisolone foam enema, or prednisolone suppositories. Once at night. |
*a progestogen may be more appropriate as an agent to treat anorexia for long term use, for example:
- Megesterol acetate 80-160mg OD PO in the morning or Medroxyprogesterone acetate 400mg OD to BD PO in the morning
Parenteral Dexamethasone:
- given SC or IV, dose depends on indication
- precipitates easily so usually best to give in separate syringe
Approximate relative potencies of steroids:
Steroid | Route of Administration | Equivalent Anti-inflammatory dose |
Dexamethasone | Oral/subcutaneous/IV/IM | 2mg |
Prednisolone | Oral/rectal | 15mg |
Hydrocortisone | Oral/IM/IV/rectal | 60mg |
The respective summary of product characteristics must be checked before prescribing the drugs described.
Reference:
- West Midlands Palliative Care Physicians (2007). Palliative care - guidelines for the use of drugs in symptom control
- Dr Michael Cushen, St Elizabeth Hospice, Ipswich 5/9/96
- West Midlands Palliative Care Physicians (2012). Palliative care - guidelines for the use of drugs in symptom control.
syringe drivers in palliative care
approximate relative potencies of steroids used in palliative care